Krovat Eva M, Langer Thierry
Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Innrain 52a, A-6020 Innsbruck, Austria.
J Med Chem. 2003 Feb 27;46(5):716-26. doi: 10.1021/jm021032v.
Chemical feature based pharmacophore models were elaborated for angiotensin II receptor subtype 1 (AT(1)) antagonists using both a quantitative and a qualitative approach (Catalyst HypoGen and HipHop algorithms, respectively). The training sets for quantitative model generation consisted of 25 selective AT(1) antagonists exhibiting IC(50) values ranging from 1.3 nM to 150 microM. Additionally, a qualitative pharmacophore hypothesis was derived from multiconformational structure models of the two highly active AT(1) antagonists 4u (IC(50) = 0.2 nM) and 3k (IC(50) = 0.7 nM). In the case of the quantitative model, the best pharmacophore hypothesis consisted of a five-features model (Hypo1: seven points, one hydrophobic aromatic, one hydrophobic aliphatic, a hydrogen bond acceptor, a negative ionizable function, and an aromatic plane function). The best qualitative model consisted of seven features (Hypo2: 11 points, two aromatic rings, two hydrogen bond acceptors, a negative ionizable function, and two hydrophobic functions). The obtained pharmacophore models were validated on a wide set of test molecules. They were shown to be able to identify a range of highly potent AT(1) antagonists, among those a number of recently launched drugs and some candidates presently undergoing clinical tests and/or development phases. The results of our study provide confidence for the utility of the selected chemical feature based pharmacophore models to retrieve structurally diverse compounds with desired biological activity by virtual screening.
采用定量和定性两种方法(分别为Catalyst HypoGen算法和HipHop算法),构建了基于化学特征的血管紧张素II 1型受体(AT(1))拮抗剂药效团模型。用于生成定量模型的训练集由25种选择性AT(1)拮抗剂组成,其IC(50)值范围为1.3 nM至150 microM。此外,从两种高活性AT(1)拮抗剂4u(IC(50)=0.2 nM)和3k(IC(50)=0.7 nM)的多构象结构模型中得出了定性药效团假设。在定量模型中,最佳药效团假设由一个五特征模型组成(Hypo1:七个点,一个疏水芳香基团、一个疏水脂肪族基团、一个氢键受体、一个可电离负离子功能基团和一个芳香平面功能基团)。最佳定性模型由七个特征组成(Hypo2:11个点,两个芳香环、两个氢键受体、一个可电离负离子功能基团和两个疏水功能基团)。所获得的药效团模型在大量测试分子上进行了验证。结果表明,它们能够识别一系列高效的AT(1)拮抗剂,其中包括一些最近上市的药物以及一些目前正在进行临床试验和/或开发阶段的候选药物。我们的研究结果为基于所选化学特征的药效团模型通过虚拟筛选检索具有所需生物活性的结构多样化合物的实用性提供了信心。